Edison healthcare quarterly: A boost for allergy immunotherapy

Edison healthcare quarterly: A boost for allergy immunotherapy

Published on 5 March 2014

Welcome to the Edison healthcare quarterly, which contains profiles of 77 companies under coverage.

The book opens with an overview of allergy immunotherapy by Lala Gregorek. Investor interest in allergy immunotherapy (AIT) has been revived by the announcement of Circassia’s intended £200m IPO on the London Stock Exchange coupled with positive FDA Advisory Committee (AdCom) recommendations for the approval of three respiratory allergy immunotherapy tablets. These AdCom discussions also have important repercussions for the wider therapeutic modality. The expert panel confirmed significant US market potential for novel AITs and provided insight into FDA requirements for trial design and approval of respiratory AIT products, facilitating the path to approval for other companies looking to enter the US market, including Circassia.

Download PDF

Energy & Resources

ASX Spotlight Conference – London, 6 March 2014

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free